Exhibit 99. 1
Sage Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Pipeline
and Business Progress
Achieved $7.4 million in ZURZUVAE
(zuranolone) collaboration revenue during the second quarter of 2024 (50% of the net revenues recorded by Biogen), representing 19% growth from the first quarter
More than 1,400 prescriptions shipped and delivered during the second quarter of 2024, nearly doubling from the first quarter
Dalzanemdor (SAGE-718) topline data from the LIGHTWAVE (Alzheimers Disease) and DIMENSION
(Huntingtons Disease) Studies expected in late 2024; primary endpoint for DIMENSION Study adjusted from HD-CAB composite to the Symbol Digit Modalities Test (SDMT)
SAGE-324 did not meet the primary endpoint in participants with essential tremor (ET); Sage and
Biogen terminated clinical development for the ET program
Cash, cash equivalents and marketable securities of $647 million as
of June 30, 2024
CAMBRIDGE, Mass. July 31, 2024 Sage Therapeutics, Inc. (Nasdaq: SAGE), a
biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the second quarter ended June 30, 2024.
We are pleased with the strength of ZURZUVAEs early commercial launch performance and its positive, real-world impact on women suffering from PPD.
Supported by several tailwinds, including increasing demand among a mix of providers, particularly OBGYNs, we believe ZURZUVAE is well-positioned to become the first line therapy and standard of care for women with PPD, said Barry Greene,
Chief Executive Officer at Sage Therapeutics. While we are deeply disappointed by the results from the KINETIC 2 study and for the essential tremor community, we remain focused on progressing our pipeline and look forward to additional
clinical data readouts expected in late 2024.
Second Quarter 2024 Portfolio Updates
Sage is advancing a portfolio of internally discovered novel chemical entities with the potential to become differentiated products designed to improve brain
health by targeting the GABAA and NMDA receptor systems. Dysfunction in these systems is thought to be at the core of numerous neuropsychiatric disorders.
Postpartum Depression Commercial Products
ZURZUVAE
was approved by the FDA in August 2023 as the first-and-only oral treatment specifically indicated for adults with postpartum depression (PPD). ZURZUVAE was made
commercially available in December 2023. ZURZUVAE is being developed and commercialized in collaboration with Biogen Inc. Sage also commercializes ZULRESSO® (brexanolone) CIV injection in the
treatment of PPD.
ZURZUVAE
Sage and
its collaborator, Biogen, are focused on the goal of establishing ZURZUVAE as the first line therapy and standard of care for women with PPD. The companies are utilizing a specialty pharmacy distribution model by which ZURZUVAE is shipped directly
to women with PPD who are prescribed the treatment.
As of the second quarter ended June 30, 2024, the following results had been achieved: